Abstract Number: 2081 • ACR Convergence 2024
Proteomic Profiling of Urine Reveals Biomarker Candidates for Idiopathic Inflammatory Myopathies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare heterogeneous group of autoimmune diseases characterized by immune-mediated muscle injury. We aimed to examine urine proteomic signatures…Abstract Number: 2323 • ACR Convergence 2024
The Effect of Biologic Therapies on Serum Metabolic Biomarkers in Patients with Psoriatic Arthritis
Background/Purpose: Biologic therapies, such as tumor necrosis factor-alpha inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i) may affect the cardio-metabolic profile of patients with psoriatic arthritis (PsA).…Abstract Number: 2535 • ACR Convergence 2024
The Lipidomic and Proteomic Profiles in Antiphospholipid Syndrome Patients Are Intricately Linked to Disease Pathogenesis and Modulated by Ubiquinol Supplementation
Background/Purpose: This study aims to:1) Characterize the circulating lipidomic and proteomic profiles of APS patient and analyse its association with clinical features.2) Investigate the short-term…Abstract Number: 2691 • ACR Convergence 2024
Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…Abstract Number: 0098 • ACR Convergence 2024
Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Background/Purpose: Heat shock protein 90 alpha (HSP90α) is an epichaperone present ubiquitously inside the cell, whose dimers function as a foldase that helps the correct…Abstract Number: 0462 • ACR Convergence 2024
Circulating Mediators of Endothelial Dysfunction as Predictors of Incident Heart Failure in Rheumatoid Arthritis
Background/Purpose: Endothelial dysfunction, leading to myocardial inflammation and dysfunction, may drive a heightened risk of heart failure (HF) in people with rheumatoid arthritis (RA). Circulating…Abstract Number: 0574 • ACR Convergence 2024
14-3-3 Eta (η) Auto-Antibody as a Diagnostic Marker in Axial Spondyloarthritis: A Longitudinal Study
Background/Purpose: Diagnosis of axial spondyloarthritis (AxSpA) is challenging and often delayed primarily due to the lack of sensitive and specific markers needed for accurate and…Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…Abstract Number: 0838 • ACR Convergence 2024
The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…Abstract Number: 0964 • ACR Convergence 2024
Engaging the PD-1 Pathway Attenuates Inflammation Associated Fibrosis in Systemic Sclerosis Fibroblasts and a Preclinical Mouse Model
Background/Purpose: The precise molecular mechanisms driving fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) remain to be elucidated. The immune regulatory programmed cell death protein 1…Abstract Number: 1281 • ACR Convergence 2024
The Brazilian Registry of Juvenile Dermatomyositis: Relationship Between Ultraviolet Radiation and Laboratory Markers of Juvenile Dermatomyositis in a Tropical Country
Background/Purpose: Ultraviolet (UV) waves are risk factors for juvenile dermatomyositis (JDM), when compared to other types of myositis without skin involvement. Patients with JDM have…Abstract Number: 1553 • ACR Convergence 2024
Safety, Pharmacokinetics, Clinical Efficacy and Exploratory Biomarker Results from a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Enpatoran in Active Systemic and Cutaneous Lupus Erythematosus (SLE/CLE)
Background/Purpose: Enpatoran, a highly selective, potent and reversible dual toll-like receptor 7/8 (TLR7/8) inhibitor, targets key innate and adaptive immune processes involved in the pathogenesis…Abstract Number: 1792 • ACR Convergence 2024
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…Abstract Number: 2094 • ACR Convergence 2024
Cross-sectional Associations of Radiographic Multiple Joint Osteoarthritis and Pain with Demographic and Clinical Characteristics: Design of a Multi-modal Study in Human and Pet Dogs
Background/Purpose: Multiple joint osteoarthritis (MJOA) is a progressive, highly prevalent disease affecting millions of Americans and as well as pet dogs. This preliminary analysis sought…Abstract Number: 2338 • ACR Convergence 2024
TNF Inhibitor Therapy Increases Absolute Lymphocyte Count Which Is Associated with Lower Mortality in Patients with Psoriatic Arthritis
Background/Purpose: Pathogenic inflammation in psoriatic arthritis (PsA) includes TNF pathway engagement, and this is associated with morbidity. Recently, we observed lower absolute lymphocyte count (ALC)…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 96
- Next Page »